.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Novartis
Express Scripts
Dow
Healthtrust
Moodys
Deloitte
Fuji
Johnson and Johnson
Julphar

Generated: September 20, 2017

DrugPatentWatch Database Preview

Cubist Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for CUBIST PHARMS LLC, and what generic alternatives to CUBIST PHARMS LLC drugs are available?

CUBIST PHARMS LLC has five approved drugs.

There are sixteen US patents protecting CUBIST PHARMS LLC drugs on CUBIST PHARMS LLC drugs in the past three years.

There are two hundred and thirty-three patent family members on CUBIST PHARMS LLC drugs in forty-two countries.

Summary for Applicant: Cubist Pharms Llc

Patents:16
Tradenames:5
Ingredients:4
NDAs:5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
POWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
TABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
TABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
TABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
CUBICIN RF
daptomycin
POWDER;INTRAVENOUS021572-003Jul 6, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
POWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
SIVEXTRO
tedizolid phosphate
POWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cubist Pharms Llc
CUBICIN
daptomycin
POWDER;IV (INFUSION)021572-001Sep 12, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Cubist Pharms Llc
ZERBAXA
ceftolozane sulfate; tazobactam sodium
POWDER;IV (INFUSION)206829-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Cubist Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms Llc
CUBICIN
daptomycin
POWDER;INTRAVENOUS021572-002Sep 12, 2003► Subscribe► Subscribe
Cubist Pharms Llc
CUBICIN
daptomycin
POWDER;IV (INFUSION)021572-001Sep 12, 2003► Subscribe► Subscribe
Cubist Pharms Llc
CUBICIN
daptomycin
POWDER;INTRAVENOUS021572-002Sep 12, 2003► Subscribe► Subscribe
Cubist Pharms Llc
CUBICIN
daptomycin
POWDER;IV (INFUSION)021572-001Sep 12, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CUBIST PHARMS LLC drugs

Drugname Dosage Strength Tradename Submissiondate
fidaxomicin
Tablets200 mg
DIFICID
5/27/2015
daptomycin
For Injection500 mg/vial
CUBICIN
11/19/2008

Non-Orange Book Patents for Cubist Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,507,564Tiacumicin production► Subscribe
9,163,043Oxazolidinone derivatives► Subscribe
8,883,986Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof► Subscribe
8,728,796Tiacumicin production► Subscribe
9,624,250Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate► Subscribe
8,835,382Lipopeptide compositions and related methods► Subscribe
9,662,397Lipopeptide compositions and related methods► Subscribe
8,518,899Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof► Subscribe
9,044,485Ceftolozane antibiotic compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Cubist Pharms Llc Drugs

Country Document Number Estimated Expiration
Peru15172012► Subscribe
World Intellectual Property Organization (WIPO)2008091554► Subscribe
New Zealand620458► Subscribe
South Korea20050053598► Subscribe
Mexico2012005993► Subscribe
European Patent Office2504353► Subscribe
South Korea20080064177► Subscribe
Hong Kong1155747► Subscribe
HungaryE027757► Subscribe
European Patent Office2860241► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Cubist Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0727Netherlands► SubscribePRODUCT NAME: FIDAXOMICINE; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111207
2016 00004Denmark► SubscribePRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
2015 00048Denmark► SubscribePRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325
C0028France► SubscribePRODUCT NAME: FIDAXOMICINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111207
943Luxembourg► SubscribePRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
C0004France► SubscribePRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
0759Netherlands► SubscribePRODUCT NAME: TEDIZOLID, DESGEWENST IN DE VORM VAN EEN ESTER, IN HET BIJZONDER EEN FOSFAAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/991 20150323
2015 00020Denmark► SubscribePRODUCT NAME: FIDAXOMICIN; REG. NO/DATE: EU/1/11/733/001-004 20111207
/2015Austria► SubscribePRODUCT NAME: FIDAXOMICIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/733/001 - 004 (MITTEILUNG) 20111207
2015 00020Denmark► SubscribePRODUCT NAME: FIDAXOMICIN ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/11/733/001-004 20111205
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Moodys
AstraZeneca
Cipla
Cantor Fitzgerald
Chubb
Chinese Patent Office
Novartis
US Army
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot